Drug search by name

Dilantin and Blood dyscrasias

Result of checking the interaction of drug Dilantin and disease Blood dyscrasias for safety when used together.

Check result:

Dilantin <> Blood dyscrasias

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Hematologic toxicities have been associated with the use of hydantoin anticonvulsants, particularly mephenytoin. Thrombocytopenia, leukopenia, neutropenia, agranulocytosis, pancytopenia and, rarely, hemolytic anemia, aplastic anemia and pure red cell aplasia have been reported. Therapy with hydantoin anticonvulsants should be administered cautiously in patients with preexisting blood dyscrasias and/or bone marrow depression. Complete blood counts, including platelets, should be performed prior to initiating therapy and regularly for several months thereafter. For mephenytoin, the manufacturer recommends performing counts after 2 weeks on a low dosage, after another 2 weeks when full dosage is reached, then monthly for a year, and every 3 months thereafter. Marked depression of blood counts may be indication for withdrawal of hydantoin therapy.

References:

"Product Information. Mesantoin (mephenytoin)" Novartis Pharmaceuticals, East Hanover, NJ.
Cacatian AA, Rando J "Diphenylhydantoin-induced pseudolymphoma syndrome with severe thrombocytopenia." N Y State J Med June (1981): 1085-7
Rawanduzy A, Sarkis A, Rovit RL "Severe phenytoin-induced bone marrow depression and agranulocytosis treated with human recombinant granulocyte-macrophage colony- stimulating factor. Case report." J Neurosurg 79 (1993): 121-4
"Product Information. Dilantin (phenytoin)." Parke-Davis, Morris Plains, NJ.
Schweiger FJ, Kelton JG, Messner H, et al "Anticonvulsant-induced marrow suppression and immune thrombocytopenia." Acta Haematol 80 (1988): 54-8
"Product Information. Cerebyx (fosphenytoin)." Parke-Davis, Morris Plains, NJ.
Arbiser JL, Goldstein AM, Gordon D "Thrombocytopenia following administration of phenytoin, dexamethasone and cimetidine: a case report and a potential mechanism." J Intern Med 234 (1993): 91-4
Thompson DF, Gales MA "Drug-induced pure red cell aplasia." Pharmacotherapy 16 (1996): 1002-8
Travin M, Macris NT, Block JM, Schwimmer D "Reversible common variable immunodeficiency syndrome induced by phenytoin." Arch Intern Med 149 (1989): 1421-2
"Product Information. Peganone (ethotoin)" Abbott Pharmaceutical, Abbott Park, IL.
Dessypris EN, Redline S, Harris JW, Krantz SB "Diphenylhydantoin-induced pure red cell aplasia." Blood 65 (1985): 789-94
Eisenstein SJ, Coleman GC "Reversible bone marrow granulomata and fever induced by phenytoin administration." J Fam Pract 29 (1989): 564-5
Guerra IC, Fawcett WA, Redmon AH, et al "Permanent intrinsic B cell immunodeficiency caused by phenytoin hypersensitivity." J Allergy Clin Immunol 77 (1986): 603-8